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Background: We hypothesize that among patients with lung cancers 
the KRAS/EGFR mutation profile and overall survival of collegiate 
smokers (former smokers who smoked between 101 lifetime ciga-
rettes and 5 pack-years) are distinct from those of never smokers and 
former smokers with 15 pack-years or more.
Methods: We collected age, sex, stage, survival, and smoking his-
tory for patients evaluated from 2004 to 2009 with advanced stage 
lung cancers and known KRAS/EGFR status. Mutation profile and 
overall survival were compared using Fisher’s exact test and log-rank 
test, respectively.
Results: Data were available for 852 patients with advanced-stage 
lung cancers with known KRAS/EGFR status, of which 6% were 
collegiate smokers, 36% were never smokers, and 30% were former 
smokers with 15 pack-years or more. The mutation profile of col-
legiate smokers (15% KRAS mutations, 27% EGFR mutations) was 
distinct from those of never smokers (p < 0.001) and former smokers 
with 15 pack-years or more (p < 0.001) and not significantly dif-
ferent from those of former smokers with 5 to 15 pack-years (p = 
0.9). Median overall survival for collegiate smokers was 25 months, 
compared with 32 months for never smokers (p = 0.4), 33 months for 
former smokers with 5 to 15 pack-years (p = 0.48), and 21 months for 
former smokers with 15 pack-years or more (p = 0.63).
Conclusions: Collegiate smokers with advanced-stage lung cancers 
represent a distinct subgroup of patients with a higher frequency of 
KRAS mutations and lower frequency of EGFR mutations compared 
with never smokers. These observations reinforce the recommenda-
tion for routine mutation testing for all patients with lung cancers and 
that no degree of tobacco exposure is safe.
Key Words: Collegiate smokers, Non–small-cell lung cancers, 
Epidermal growth factor receptor mutation, KRAS mutation.
(J Thorac Oncol. 2013;8: 123–125)
The discovery of driver lesions in epidermal growth factor receptor (EGFR), KRAS, and anaplastic lymphoma kinase 
(ALK) has led to the identification of distinct genetic subtypes 
of lung cancers. This information is revolutionizing the treat-
ment of lung cancer. We have demonstrated that the frequency 
of KRAS mutations increases and EGFR mutation decreases 
with greater tobacco exposure, and EGFR mutations are less 
common in patients who smoked greater than 15 pack-years.1,2 
These EGFR mutations predict sensitivity to EGFR tyrosine 
kinase inhibitors.3–5 By contrast, lung cancers harboring KRAS 
mutations are found in patients with a variety of tobacco expo-
sures ranging from never smokers to heavy smokers, whereas 
patients whose tumors harbor ALK rearrangements are more 
likely never or light smokers compared with those patients 
whose tumors do not harbor ALK rearrangements.6,7
For patients with advanced lung cancers, we have shown 
that cigarette smoking is associated with worse survival after 
a diagnosis.8 We have also demonstrated that patients with 
advanced lung cancers harboring KRAS mutations have a 
shorter survival compared with those of patients with tumors 
harboring EGFR mutations and patients whose tumors are 
wild type for KRAS and EGFR.9
Whether the tobacco exposure of collegiate smokers, 
individuals who are former smokers with a lifetime expo-
sure between 101 cigarettes and 5 pack-years, is sufficient to 
impact their prognosis is unknown. We hypothesize that the 
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KRAS and EGFR mutation profile and overall survival of col-
legiate smokers will be distinct from never smokers and for-
mer smokers with 15 pack-years or more smoking histories. 
Fifteen pack-years or more was the chosen number as we had 
previously determined that that EGFR mutation frequency 
above that amount of cigarette exposure was significantly dif-
ferent than the frequency seen in never smokers.1
PATIENTS AND METHODS
This cohort includes patients evaluated at Memorial 
Sloan-Kettering Cancer Center between 2004 and 2009 with 
known KRAS and EGFR status and advanced-stage lung 
cancers (stage IIIB / IV by the American Joint Committee 
on Cancer staging manual, 6th edition) at the time of ini-
tial diagnosis or at the time of recurrent disease after prior 
surgery or radiation. Patients with squamous and small-cell 
lung cancers did not undergo EGFR/KRAS analysis. Patients 
with lung cancers evaluated at Memorial Sloan-Kettering 
Cancer Center completed a prospective, self-administered 
smoking questionnaire at the time of their initial visit. The 
history of smoking, number of pack-years smoked, and years 
since they quit smoking were determined using the smoking 
questionnaire. We obtained demographic and clinical infor-
mation regarding sex, race, age, stage, and survival. EGFR 
exon 19 deletions and EGFR exon 21 L858R amino acid 
substitutions were identified by previously reported muta-
tion-specific polymerase chain reaction–based methods.10–12 
KRAS codon 12 and 13 mutation identification was per-
formed by  mass-spectrometry (Sequenom, Inc., San Diego, 
CA)-based genotyping or direct sequencing. ALK testing was 
not available for patients before 2009 and was not evaluated 
in this cohort. Medical record review was performed with a 
waiver of authorization approved by our Institutional Review 
Board. Mutation profile was compared across groups using 
the Fisher’s exact test. Overall survival after diagnosis with 
advanced-stage lung cancer was estimated using Kaplan–
Meier method and compared across groups using the log-rank 
test. Patients alive at the end of the study were censored at the 
time of the last available follow-up.
Patients were categorized as never smokers if they had 
smoked 100 or fewer lifetime cigarettes, current smokers if 
they continued to smoke or quit less than 12 months before 
completion of the smoking questionnaire, and former smok-
ers if they quit smoking at least 12 months before comple-
tion of the smoking questionnaire. Race was reported by the 
patient.
RESULTS
Detailed smoking history and clinical data were avail-
able for 852 patients with advanced-stage lung cancers (492 
women, 360 men). Ninety-seven percent of this patient popu-
lation had adenocarcinoma, and the remaining 3% included 
patients with non–small-cell lung cancer not otherwise speci-
fied and large cell neuroendocrine carcinoma. Demographic 
characteristics are summarized in Table 1. Collegiate smokers 
had stopped smoking a median of 30 years before diagnosis 
(range, 1–60 years).
Mutation profiles are depicted in Figure 1. The mutation 
profile of collegiate smokers is different from those of patients 
who had never smoked (p < 0.001) and of former smokers 
who had smoked 15 pack-years or more (p < 0.001) but simi-
lar to that of patients who were former smokers with 5 to 15 
pack-years (p = 0.9). Among former smokers with smoking 
histories of 15 pack-years or more, 40% had KRAS mutations, 
11% had EGFR mutations, and 49% were wild type for KRAS 
and EGFR mutations.
Median overall survival after diagnosis of advanced-stage 
lung cancer for collegiate smokers was 25 months, compared 
with 32 months for never smokers (p = 0.4), 21 months for for-
mer smokers with 15 pack-years or more (p = 0.63), and 33 
months for former smokers with 5 to 15 pack-years (p = 0.48).
DISCUSSION
Many persons with lung cancers state that they only 
smoked in college or for just a few years when they were 
younger. Because we had collected smoking questionnaires 
from all patients with advanced-stage lung cancers prospec-
tively, we were in a position to assess whether the mutational 
profile and course of lung cancer were different between indi-
viduals who never smoked and those with greater exposures 
to cigarette smoking. We defined collegiate smokers as for-
mer smokers who have smoked between 101 lifetime ciga-
rettes and 5 pack-years. On the basis of these data, collegiate 
smokers with advanced-stage lung cancers represent a distinct 
group of patients with a higher percentage of KRAS muta-
tions and lower percentage of EGFR mutations as compared 
with never smokers. The median overall survival of collegiate 
smokers was not significantly different from never smokers, 
former smokers with 5 to 15 pack-years, and former smokers 
with 15 pack-years and more, but not significantly different in 
this relatively small cohort.
Heavier cigarette-smoking history is associated with 
decreased survival after a diagnosis of advanced-stage lung 
cancer.8 Likewise, recent work has demonstrated that any 
amount of smoking exposure greater than 1 pack-year can 
impact the likelihood of EGFR and KRAS mutations among 
TABLE 1.  Patient Characteristics
N %
Men 360 42
Women 492 58
Median age (range), yrs 64 (26–92)
Smoking history
 Never smoker 307 36
 Collegiate smoker 55 6
 Former smoker with 5 to 15 pack-yrs 61 7
 Former smoker with ≥15 pack-yrs 251 30
 Current smoker 178 21
Race
 White 710 83
 Asian 67 8
 Unknown/other 75 9
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patients with lung cancers.2 Although the majority of gene 
expression alterations associated with smoking return 
to the levels associated with never smokers, expression 
of a subset of genes remains affected, even decades after 
smoking cessation.13 Building on this work, these data serve 
as a reminder that the effects of even minimal amounts of 
cigarette smoking decades earlier influence the biology and 
perhaps the outcome of lung cancers. In addition, many 
clinicians continue to choose EGFR-targeted therapy based 
on clinical history, including never or collegiate smoking 
history. These data reinforce the necessity of performing 
routine molecular testing on all patients with lung cancers. 
Finally, these data remind us that no amount of cigarette 
smoking is safe.
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FIGURE 1.  Mutation profiles for 
never smokers, collegiate smokers, 
and former smokers with 15 pack-
years or more of smoking histories.
